Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study

202144 citationsJournal Articlegold Open Access

Authors

CARACAS study met its primary endpoint in arm B, documenting promising activity of dual EGFR and PD-L1 blockade in aSCAC.

Good health and well-being

Published in: Journal for ImmunoTherapy of Cancer

Volume 9, Issue 11, pp. e002996-e002996

Field-Weighted Citation Impact: 6.69